Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
5
83%

Phase Distribution

5

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
5(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(1)
Other(1)

Detailed Status

Completed4
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
80.0%
Most Advanced
Phase 1

Trials by Phase

Phase 15 (100.0%)

Trials by Status

completed467%
terminated117%
unknown117%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_1

A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis

NCT01443260
completedphase_1

Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors

NCT00794131
completedphase_1

Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma

NCT01766739
unknown

Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care

NCT03420430
terminatedphase_1

GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers

NCT02714374
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT01443260Phase 1

A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis

Completed
NCT00794131Phase 1

Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors

Completed
NCT01766739Phase 1

Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma

Completed
NCT03420430

Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care

Unknown
NCT02714374Phase 1

GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers

Terminated
NCT01584284Phase 1

Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer

Completed

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6